Eli Lilly & Co. (LLY) Financials
Key financial figures for Eli Lilly & Co. (Q2 2026).
Lilly's Q2 2026 revenue jumped 48% year-over-year to $22.97 billion on continued Mounjaro and Zepbound demand, and the company raised full-year 2026 revenue guidance to $85-87 billion. Total revenue of $22.97 billion, up 47.7% year-over-year, driven by tirzepatide (Mounjaro + Zepbound) demand across geographies GAAP diluted EPS of $7.94 and non-GAAP adjusted diluted EPS of $8.38 for the quarter Mounjaro worldwide revenue reached $9.94 billion and Zepbound U.S. revenue reached $4.93 billion, combining for $14.87 billion in tirzepatide revenue, up from $12.82 billion in Q1 2026 Jardiance revenue outside the U.S. On the outlook: FY2026 revenue of $85 billion to $87 billion (raised from $82 billion to $85 billion) and non-GAAP adjusted diluted EPS of $35.50 to $36.50 (narrowed from $35.50 to $37.00). Figures are for Q2 2026, as Eli Lilly and Company reported them.
- Revenue
- $23.0B
- Net Income
- $7.1B
- EPS
- $7.95
- Total Assets
- $142.3B
- Operating Cash Flow
- $10.7B
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $23.0B | $7.1B | $7.94 | 54.22% | $7.8B |
| Q1 FY2026 | $19.8B | $7.4B | $8.26 | 49.39% | $3.0B |
| Q4 FY2025 | $19.3B | $6.6B | $7.39 | 46.59% | $678M |
| Q3 FY2025 | $17.6B | $5.6B | $6.21 | 47.65% | $8.6B |
| Q2 FY2025 | $15.6B | $5.7B | $6.29 | 45.13% | $1.3B |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $65.2B | $20.6B | $22.95 | 45.56% | $9.0B |
| FY2024 | $45.0B | $10.6B | $11.71 | 37.83% | $414M |
| FY2023 | $34.1B | $5.2B | $5.80 | 31.61% | -$3.2B |
Frequently asked questions
What was Eli Lilly and Company's revenue last quarter?
Eli Lilly and Company reported revenue of $22.97 billion for Q2 FY2026, up 47.7% from the same period a year earlier.
Is Eli Lilly and Company profitable?
Yes. Eli Lilly and Company reported net income of $7.10 billion for Q2 FY2026, a net margin of 30.88% on revenue.
How has Eli Lilly and Company's margin trended?
Operating margin was 54.22% in Q2 FY2026, compared with 45.13% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Eli Lilly and Company generate?
Eli Lilly and Company generated free cash flow of $7.76 billion in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Eli Lilly & Co. on SentiSense, with up to forty quarters and twenty fiscal years of history.